Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Microbial cocktails join fecal transplants in IBD treatment trials

Nature Biotechnology volume 33, pages 787–788 (2015)Cite this article

Subjects

A Correction to this article was published on 01 September 2015

This article has been updated

Big players' interest in microbiome therapeutics for IBD ramped up in January 2015 when Johnson & Johnson (J&J), New Brunswick, New Jersey, entered a potential $241-million alliance to obtain development rights to a bacterial cocktail for treating the disorder, which encompasses both Crohn's disease and ulcerative colitis. J&J-owned Janssen, of Titusville, New Jersey, licensed from Vedanta Biosciences, a live mix of Clostridium strains to stimulate and modulate the mucosal immune system in the gut. In the same week, startup biotech Second Genome, located in S. San Francisco, California, announced a phase 1 trial for its microbiome-modulating IBD drug. Seres, for its part, has a follow-on program in IBD. Its SER-287, pegged to begin human clinical studies by the end of 2015, is a bacterial mixture designed to address changes in IBD patients (dysbiosis), which includes higher levels of Enterobacteriaceae and lower levels of Clostridiales.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Change history

  • 08 September 2015

    In the version of this article initially published, IBD was identified as irritable bowel disease, rather than inflammatory bowel disease. The error has been corrected in the HTML and PDF versions of the article.

  • 01 September 2015

    In the August 2015 issue, in the article “Microbial cocktails join fecal transplants in IBD treatment trials,” IBD was identified as irritable bowel disease, rather than inflammatory bowel disease. The error has been corrected in the HTML and PDF versions of the article. In the same issue, in the article “Oxitec trials GM sterile moth to combat agricultural infestations,” trials with a genetically modified moth were described as the first to be used in agriculture.

Author information

Authors and Affiliations

  1. Boca Raton, Florida

    Mark Ratner

Authors
  1. Mark Ratner
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ratner, M. Microbial cocktails join fecal transplants in IBD treatment trials. Nat Biotechnol 33, 787–788 (2015). https://doi.org/10.1038/nbt0815-787

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0815-787

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing